Evaluation of circulating miRNAs in the patents with intractable progressive fibrosis of the lung, for the effective differential diagnosis and therapeutic strategy.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K09227
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Tohoku Medical and Pharmaceutical University
• Principal Investigator: EBINA Masahito 東北医科薬科大学, 医学部, 教授 (10280885)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肺線維症 / 循環miRNAs / IPF / f-NSIP / PPFE / 難治性 / 治療戦略

Outline of Final Research Achievements

Idiopathic pulmonary fibrosis (IPF), fibrotic non-specific interstitial pneumonia (f-NSIP), and pulmonary parenchymal fibro-elastosis (PPFE) are notorious progressive diseases of pulmonary fibrosis, because of their high intractability. To find out and construct effective treatment strategy against these progressive fibrosis of the lung, we measured and analyzed the circulating miRNA of the patients before and after treatment with medication by anti-pulmonary fibrosis, Nintedanib, Pirfenidone, Tacrolimus, and/or Steroids. These results were compared with our previous results of alteration of circulating miRNAs in the animal models, bleomycin-induced lung fibrosis.

Free Research Field

呼吸器内科